Shenzhen Hepalink Invests $60 Million in Latest TPG Biotech Fund

Shenzhen Hepalink Pharma, China's major heparin API company, will invest $60 million in TPG Biotechnology Partners V. Two years ago, Hepalink put $22 million in TPG Biotechnology Partners IV. TPG, a US-headquartered firm known primarily as a PE specialist, invests in all stages of development in its biotech fund. It will pursue global opportunities in therapeutics, medical devices and healthcare services. More details.... Stock Symbol: (SHZ: 002399) Share this with colleagues: // //